

# DIRECT-TO-PATIENT PROGRAM



The Direct-to-Patient Program for VIMPAT enables patients to purchase **60 tablets of any branded VIMPAT® (lacosamide) film coated tablets for \$84.99, or 180 tablets for \$239.97** with a valid prescription from your healthcare provider.

\*Eligibility Terms and Conditions apply. See below for full Terms and Conditions.

## How to Directly Purchase Branded VIMPAT at This Discounted Cash Price

1

Have your healthcare provider send your prescription for VIMPAT directly to Transition Pharmacy.



### How to e-Prescribe VIMPAT

Transition Pharmacy information for processing e-prescription through an EMR system:

Name: Transition Pharmacy	Pharmacy Type: Retail
City: Trevose	State: PA Zip: 19053
NPI #: 1336325265	NCPDP #: 3989603



Prescribe branded VIMPAT by calling (844) 721-4882

2

Approximately 24-48 hours after Transition Pharmacy receives the prescription, you will receive a call from Transition Pharmacy. You will be asked to complete a 3rd party insurance opt-out that captures (1) your consent to enroll in the D2P program, and (2) your agreement to comply with the program's terms and conditions, including not using your insurance coverage for any VIMPAT purchased through the program. You will also be asked for your form of payment. All major credit cards, including FSA/HSA cards are accepted.

*Choosing to opt-out of 3rd party insurance for branded VIMPAT through this program will not impact your insurance coverage.*

3

If you don't receive a call within 48 hours of your healthcare provider prescribing VIMPAT, please call Transition Pharmacy at 1-844-721-4882.

4

Your VIMPAT prescription will be processed and delivered directly to your home at no additional cost to you. Your VIMPAT prescription will arrive within a few days.

5

Pharmacists are on hand to answer any questions you have about the Direct-to-Patient Program for VIMPAT.

#### \*Eligibility Terms and Conditions:

- Direct purchase option is only available for VIMPAT® (lacosamide) CV tablets prescriptions.
- Patient must have a valid prescription consistent with the FDA-approved product labeling for VIMPAT to participate in the Direct-to-Patient Program for VIMPAT.
- The Direct-to-Patient Program for VIMPAT is available to residents of the United States and all United States Territories only.
- Program is not available where prohibited by law.
- The Direct-to-Patient Program for VIMPAT operates outside of any third-party insurance. Neither the patient nor the pharmacy nor anyone else acting on the patient's behalf may submit any claim for reimbursement for product dispensed pursuant to this program to any third-party payer, including Medicare, Medicaid, or any other federal or state healthcare program. Out-of-pocket expenses incurred when using this program cannot be applied toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
- The Direct-to-Patient Program for VIMPAT does not include all Manufacturer products. Eligible patients may purchase the following Manufacturer products from the program: VIMPAT tablets.
- The Direct-to-Patient Program for VIMPAT is not health insurance.
- Limitations may apply.
- The Direct-to-Patient Program for VIMPAT cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
- Manufacturer reserves the right to rescind, revoke, or amend this program without notice.



Inspired by **patients.**  
Driven by **science.**

VIMPAT® is a registered trademark used under license from Harris FRC Corporation.  
©2025 UCB, Inc., 1950 Lake Park Drive, Smyrna, GA 30080. All rights reserved.  
US-VI-2500003